Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT101 vs Gemcitabine in Recurrent or Metastatic Cervical Cancer
NCT06241781Phase 2Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous tumor infiltrating lymphocytes GT101 in Cervical Cancer (CC) (2 arms), sponsored by Grit Biotechnology. Primary endpoint: Progression Free Survival at 3 years. Started Apr 2024; status: recruiting.
02
Drugs
autologous tumor infiltrating lymphocytes GT101
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06241781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241781.